|
|
Volumn 35, Issue 13, 2017, Pages 1384-1386
|
|
Is there a role for ovarian cancer screening in high-risk women?
a a a |
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BRCA1 PROTEIN;
BRCA2 PROTEIN;
CA 125 ANTIGEN;
ADVANCED CANCER;
BREAST CANCER;
CANCER MORTALITY;
CANCER SCREENING;
CANCER STAGING;
CANCER SURVIVAL;
COST EFFECTIVENESS ANALYSIS;
EARLY MENOPAUSE;
EDITORIAL;
ENDOMETRIOSIS;
ESTROGEN THERAPY;
FALSE POSITIVE RESULT;
FAMILY HISTORY;
FEMALE;
FOLLOW UP;
GENE MUTATION;
GENETIC VARIABILITY;
GROUPS BY AGE;
HIGH RISK PATIENT;
HUMAN;
METASTASIS;
MORBIDITY;
OCCULT CANCER;
ORAL CONTRACEPTIVE USE;
OVARY CARCINOMA;
PARITY;
PELVIS CANCER;
PHASE 1 CLINICAL TRIAL (TOPIC);
PHASE 2 CLINICAL TRIAL (TOPIC);
POSTMENOPAUSE;
PRIORITY JOURNAL;
RISK REDUCTION;
SALPINGECTOMY;
SALPINGOOOPHORECTOMY;
SECONDARY ANALYSIS;
TRANSVAGINAL ECHOGRAPHY;
UTERINE TUBE LIGATION;
EARLY CANCER DIAGNOSIS;
OVARY TUMOR;
UNITED KINGDOM;
CA-125 ANTIGEN;
CARCINOMA, OVARIAN EPITHELIAL;
EARLY DETECTION OF CANCER;
FEMALE;
HUMANS;
OVARIAN NEOPLASMS;
UNITED KINGDOM;
|
|
EID: 85018326828
PISSN: 0732183X
EISSN: 15277755
Source Type: Journal
DOI: 10.1200/JCO.2016.72.0045 Document Type: Editorial |
|
Times cited : (8)
|
|
References (9)
|
